Fifth Third Bancorp Has $413,000 Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Fifth Third Bancorp grew its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6,682.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 18,720 shares of the company’s stock after buying an additional 18,444 shares during the period. Fifth Third Bancorp’s holdings in Teva Pharmaceutical Industries were worth $413,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. UMB Bank n.a. increased its stake in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after acquiring an additional 2,067 shares during the period. Smithfield Trust Co increased its position in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at $50,000. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries in the third quarter worth $52,000. Finally, Venturi Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth $60,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of analyst reports. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday. Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $17.88 on Friday. Teva Pharmaceutical Industries Limited has a 52 week low of $11.62 and a 52 week high of $22.80. The stock has a market capitalization of $20.25 billion, a PE ratio of -21.03, a PEG ratio of 1.11 and a beta of 0.73. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The stock’s fifty day moving average is $19.97 and its 200-day moving average is $18.48.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 42.92%. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.37 EPS for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.